诉讼背景 - 律师事务所Levi & Korsinsky代表投资者对Charter Communications Inc提起集体诉讼 该诉讼针对在2024年7月26日至2025年7月24日期间购买公司证券、购买看涨期权或出售看跌期权的投资者 [1][2] 指控内容 - 公司被指控在可负担连接计划(ACP)终止的影响方面作出虚假陈述和/或隐瞒 声称其无法管理或迅速摆脱该计划终止带来的重大影响 [3] - 公司被指控隐瞒ACP终止对互联网用户流失和收入持续产生的实际影响 [3] - 公司被指控其运营执行未能补偿或克服ACP终止带来的影响 [3] - 公司被指控互联网用户流失及执行战略的失败给业务计划和盈利增长带来了比报告更大的风险 [3] - 公司被指控没有合理依据声称其成功执行运营、管理互联网用户流失原因或提供关于公司长期轨迹和EBITDA增长的过度乐观陈述 [3] 诉讼程序 - 遭受损失的投资者可在2025年10月14日前申请担任首席原告 参与补偿无需支付任何自付费用 [4] - 律师事务所Levi & Korsinsky拥有20年经验 曾为受损股东追回数亿美元 连续七年位列ISS证券集体诉讼服务Top 50报告 [5]

诉讼背景 - Levi & Korsinsky律师事务所代表Lineage Inc投资者提起集体诉讼 涉及NASDAQ上市公司Lineage Inc (代码LINE) [1] - 诉讼针对2024年7月26日IPO期间通过注册声明购买公司普通股的投资者 [2] 指控内容 - 公司隐瞒客户需求持续疲软事实 因新增冷库供应上线且客户正在清理疫情期间积累的过量库存 [3] - 客户为应对消费趋势变化转向维持更精益的冷库库存水平 [3] - 公司在IPO前实施的价格上涨在需求疲软环境下不可持续 [3] - 公司无法通过最低存储保证、运营效率提升或技术改进有效抵消不利趋势 [3] - 实际出现收入停滞或下降、占用率和租金价格下跌 与注册声明中稳定的收入增长、高占用率和稳定租金上涨表述不符 [3] - 公司财务业绩、业务运营和前景受到实质性损害 [3] 时间节点 - 投资者需在2025年9月30日前申请成为首席原告 [4]

公司诉讼事件 - 律师事务所Levi & Korsinsky代表投资者对Capricor Therapeutics提起集体诉讼 指控公司在2024年10月9日至2025年7月10日期间涉嫌证券欺诈 [1] - 诉讼涉及公司主力细胞疗法药物deramiocel 该药物用于治疗杜氏肌营养不良相关心肌病 [2] 产品监管进展 - 公司向投资者提供关于获得FDA生物制剂许可申请(BLA)的积极陈述 但被指控隐瞒HOPE-2试验四年安全性和有效性数据的不利信息 [2] - 2025年7月11日FDA发出完整回复函(CRL)拒绝BLA申请 理由包括缺乏有效性的实质性证据需要更多临床数据 以及化学制造与控制部分存在未解决问题 [2] 市场反应 - FDA拒绝BLA的消息导致公司股价从2025年7月10日的11.40美元/股下跌至7月11日的7.64美元/股 单日跌幅达33% [2] 法律程序 - 投资者可在2025年9月15日前申请作为首席原告参与诉讼 集体成员无需支付任何自付费用即可获得潜在赔偿 [3] - Levi & Korsinsky律师事务所过去20年为股东追回数亿美元赔偿 连续七年被ISS证券集体诉讼服务评为美国前50大证券诉讼律师事务所 [4]

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ: UNCY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-su ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/ ...

公司调查事件 - Frank R Cruz律师事务所宣布对Quanex Building Products Corporation展开调查 涉及公司可能违反联邦证券法的行为 [1] - 调查针对因投资Quanex遭受损失的投资者 可能通过索赔追回损失 [1] - 调查直接关联2025年9月4日公司发布的信息 [1]